Benzinga · Sep 30, 2026
UBS Reinstates Neutral on Icon, Announces $195 Price Target
UBS analyst Kevin Caliendo reinstates Icon (NASDAQ:ICLR) with a Neutral and announces $195 price target.
NASDAQ · ICLR
ICON Public Limited Company
Healthcare · Medical - Diagnostics & Research
$164.17
Down-$0.33 (-0.20%)
Updated Oct 10, 2026, 9:09 PM
SID Score
6.4/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 14.49B
- P/E ratio
- 24.5
- Dividend yield
- 0.00%
- 52-week range
- $66.57 – $203.91
- Volume
- 745.62K
- Avg. volume
- 993.9K
Price performance · ICLR
ICLR price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
ICLR closed at $164.17 after 21 trading sessions, down 3.04% for the selected period.
- Last close
- $164.17
- Period change
- -3.04%
- Period low
- $161.69
- Period high
- $175.57
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $167.04 | $169.85 | $163.47 | $164.17 | 745.62K |
| Oct 8, 2026 | $161.62 | $164.95 | $159.155 | $164.50 | 1.03M |
| Oct 7, 2026 | $160.93 | $165.22 | $157.375 | $164.08 | 776.24K |
| Oct 6, 2026 | $169.69 | $177.67 | $161.14 | $161.69 | 984.01K |
| Oct 5, 2026 | $161.07 | $168.76 | $160.985 | $168.33 | 932.55K |
| Oct 2, 2026 | $161.85 | $163.43 | $160.41 | $162.05 | 676.14K |
| Oct 1, 2026 | $169.99 | $170.22 | $160.90 | $161.85 | 677.23K |
| Sep 30, 2026 | $167.98 | $170.40 | $165.235 | $169.99 | 851.06K |
| Sep 29, 2026 | $174.50 | $176.70 | $169.73 | $170.35 | 1.44M |
| Sep 28, 2026 | $171.13 | $175.87 | $169.375 | $175.57 | 1.34M |
| Sep 25, 2026 | $173.80 | $174.92 | $170.435 | $172.33 | 965.9K |
| Sep 24, 2026 | $163.79 | $175.00 | $163.79 | $173.90 | 1.62M |
| Sep 23, 2026 | $167.77 | $169.28 | $163.41 | $163.90 | 1.06M |
| Sep 22, 2026 | $170.55 | $172.04 | $167.11 | $167.11 | 1.06M |
| Sep 21, 2026 | $164.61 | $169.95 | $163.16 | $169.55 | 1.03M |
| Sep 18, 2026 | $169.50 | $169.50 | $162.585 | $164.11 | 1.12M |
| Sep 17, 2026 | $175.01 | $177.50 | $169.44 | $169.68 | 1.17M |
| Sep 16, 2026 | $173.51 | $175.59 | $172.09 | $173.94 | 818.59K |
| Sep 15, 2026 | $168.02 | $172.94 | $167.715 | $172.45 | 862.42K |
| Sep 14, 2026 | $171.51 | $173.40 | $167.795 | $168.93 | 1.33M |
| Sep 11, 2026 | $165.68 | $175.63 | $165.68 | $169.31 | 1.71M |
Latest ICLR news
The latest Smart Investors Daily articles mentioning ICLR.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ICLR research
Overview
Company profile and research snapshot.
Company profile
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $205.00
- Implied upside
- —
- Analysts
- 24
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2026 | UBS | Neutral | — |
| Sep 18, 2026 | Citigroup | Neutral | — |
| Jul 31, 2026 | Citigroup | Neutral | — |
| Jul 31, 2026 | Truist Securities | Buy | — |
| Jun 30, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 22, 2026
ICON Public Limited Company’s (ICLR) Shrinking Moat Warranted an Early Departure
Marram Investment Management’s second-quarter 2026 investor letter reports a +2.7% portfolio return (net of fees), resulting in a year-to-date return of +3.2%. A copy of the letter can be downloaded here. Cumulatively, since inception, the firm has achieved a +632.4% return and a +13.7% annualized return, net of fees. Positive contributions came from MLP Energy […]
Benzinga · Sep 18, 2026
Strategic Sale: DR JOHN CLIMAX Decides To Exercise Options Worth $204K At Icon
Disclosed in a recent SEC filing on September 18, CLIMAX, Director at Icon (NASDAQ:ICLR), made a noteworthy transaction involving the exercise of company stock options. What Happened: The latest Form 4 filing on Friday
Benzinga · Sep 18, 2026
Options Exercise: Pacelli Eugene McCague At Icon Realizes $132K
In a new SEC filing on September 18, it was revealed that McCague, Board Member at Icon (NASDAQ:ICLR), executed a significant exercise of company stock options. What Happened: A notable Form 4 filing on Friday with the
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
